文献速递眼底病与葡萄膜炎

揭示他汀类药物与遗传因素在年龄相关性黄斑变性中的作用:科英布拉眼科研究-第9次报告

Unveiling Statins and Genetics in Age-Related Macular Degeneration: The Coimbra Eye Study-Report 9.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2024-01-01

科英布拉眼科研究纳入682名受试者,随访6.5年,评估他汀类药物使用与年龄相关性黄斑变性(AMD)进展及遗传风险的关联。结果显示,他汀类药物摄入使AMD进展风险降低48%;未服用他汀且高遗传风险评分者进展风险是服用他汀且低遗传风险评分者的4.25倍;未发现显著的相乘或相加交互作用。

要点

  • 他汀类药物摄入与AMD进展风险降低48%相关(校正年龄、性别、BMI、吸烟、糖尿病及遗传风险评分)。
  • 未服用他汀且高遗传风险评分者相比服用他汀且低遗传风险评分者,AMD进展风险为4.25倍(HR=4.25;95%CI 1.62-11.16;P=0.003)。
  • 未服用他汀者中,高遗传风险评分者相比低遗传风险评分者AMD进展风险升高(HR=1.80;95%CI 1.13-2.85;P=0.013)。

核心结论

  • 他汀类药物似乎对AMD进展具有保护作用,遗传因素可能在治疗反应中起作用。

研究设计与样本

  • 基于科英布拉眼科研究的分析,纳入682名受试者,进行两次访视(随访6.5年),计算由52个与AMD相关的独立变异构成的遗传风险评分。

主要发现

  • 未服用他汀者中位生存时间为7.50年,服用他汀者为7.62年(P<0.001)。
  • 他汀类药物摄入使AMD进展风险降低48%,校正年龄、性别、体质指数、吸烟、糖尿病(模型1)及遗传风险评分(模型2)。
  • 未服用他汀且高遗传风险评分者相比服用他汀且低遗传风险评分者,AMD进展风险为4.25倍(HR=4.25;95%CI 1.62-11.16;P=0.003)。
  • 未服用他汀者中,高遗传风险评分者相比低遗传风险评分者,AMD进展风险升高(HR=1.80;95%CI 1.13-2.85;P=0.013)。
  • 未发现统计学显著的相乘或相加交互作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the association of age-related macular degeneration (AMD) progression and statins, connected with AMD genetic risk, and if there is an interplay between statins and genetics. METHODS: In this analysis, 682 subjects made two visits (6.5-year follow-up) of the Coimbra Eye Study. Subjects who started taking statins at any time point between the two visits were considered. Progressors were defined as not having AMD at baseline and having any AMD at follow-up. Genetic risk scores (GRSs) were calculated individually with 52 independent variants associated with AMD. Time to progression was estimated using unadjusted Kaplan-Meier curves. An extended Cox model was used for the association between statins and GRS with the risk for AMD progression. Multiplicative and additive interactions were assessed. RESULTS: Median survival time was 7.50 years for subjects not taking statins and 7.62 for subjects taking statins (P < 0.001). Statin intake reduced the risk for progression to AMD in 48%, adjusting for age, sex, body mass index, smoking, and diabetes (model 1) and GRS (model 2). The combined effects of not taking statins and having high GRS increased the progression risk fourfold compared to taking statins and having low GRS (hazard ratio [HR] = 4.25; 95% confidence interval [CI], 1.62-11.16; P = 0.003). For subjects not taking statins, an increased risk of progression was found for those subjects with high GRS compared to subjects with low GRS (HR = 1.80; 95% CI, 1.13-2.85; P = 0.013). No statistically significant multiplicative or additive interactions were found. CONCLUSIONS: Statins seem to be protective against AMD progression, and genetics may play a role in treatment response.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Barreto P, Farinha C, Coimbra R, et al. Unveiling Statins and Genetics in Age-Related Macular Degeneration: The Coimbra Eye Study-Report 9. Invest Ophthalmol Vis Sci. 2024. PMID: 38935028. doi:10.1167/iovs.65.6.38

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。